translation missing: fr.activerecord.attributes.event.titles.recall_field_safety_notice

Selon Saudi Food & Drug Authority, ce/cet/cette translation missing: fr.activerecord.attributes.event.types.recall_field_safety_notice concerne un dispositif en/au/aux/à Saudi Arabia qui a été fabriqué par Medtronic SA.

Qu'est-ce que c'est?

Les avis de sécurité sont des communications que les fabricants de dispositifs médicaux ou leurs représentants font parvenir en particulier aux travailleurs du secteur médical, mais aussi aux utilisateurs de ces dispositifs. Les avis de sécurité concernent les actions entreprises quant aux dispositifs présents sur le marché et peuvent inclure des rappels et des alertes.

En savoir plus sur les données ici
  • Type d'événement
    Recall / Field Safety Notice
  • ID de l'événement
    mdprc 058 12 16 001
  • Date de mise en oeuvre de l'événement
    2017-05-16
  • Pays de l'événement
  • Source de l'événement
    SFDA
  • URL de la source de l'événement
  • Notes / Alertes
    Saudi data is current through January 2019. All of the data comes from the Saudi Food & Drug Authority, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Saudi Arabia.
  • Notes supplémentaires dans les données
    Report Source: NCMDR
    SFDA urges all hospitals that have devices subjected to recall, to contact the company.
  • Cause
    Medtronic identified an issue that may occur with all models of claria mri™ crt-d surescan™ and amplia mri™ crt-d surescan™ devices. the issue is a loss of lv pacing that occurs following a specific device programming sequence. whenever a patient with adaptivcrt* enabled (shipped setting) is subsequently programmed to mvp (managed ventricular pacing) mode and then re-programmed back to ddd or dddr, adaptivcrt is not re-enabled. when this programming sequence occurs, lv pacing is not delivered, despite parameters indicating adaptivcrt is enabled. this will result in rv only pacing which may be undesirable for the patient. lv pacing will remain disabled until a specific programming sequence is manually completed. * this feature adjusts crt parameter values automatically while the patient is ambulatory. if adaptivcrt is programmed to adaptive bi-v and lv, the feature can switch automatically between biventricular pacing and lv-only pacing.

Device

  • Modèle / numéro de série
    Model Name: Product Model - Amplia MRI™ CRT-D SureScan™: ( DTMB2D1, DTMB1D4, DTMB2D4 ) - Amplia MRI™ Quad CRT-D SureScan™: ( DTMB2Q1, DTMB1QQ, DTMB2QQ) - Claria MRI™ CRT-D SureScan™: ( DTMA2D1, DTMA2D4) - Claria MRI™ Quad CRT-D SureScan™: (DTMA2Q1, DTMA2QQ )
  • Description du dispositif
    Cardiac resynchronization therapy implantable defibrillator
  • Manufacturer

Manufacturer

  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Représentant du fabricant
    Medtronic Saudi Arabia
  • Source
    SFDA